Welcome to another edition of Common Ground Online. Here's what's in this week's edition:
 |
Symptom outcomes for children and adolescents who took EMPowerplus for six months or longer.*
* To ensure data accuracy, researchers included only those who reported their symptoms to Truehope for at least 60 days. |
Researchers from universities in 3 different countries recently published an analysis of how children and adolescents on the Truehope program responded to EMPowerplus over 6 or more months of use.
The researchers followed 161 children and adolescents diagnosed with either bipolar disorder, ADHD, or both. More than half reported a diagnosis of pediatric bipolar disorder alone, 25% had ADHD alone, and the remainder had both ADHD and bipolar disorder.
Researchers noted “consistently positive reported outcomes” and “general absence of adverse side effects” with the nutritional therapy.
Treatment with EMPowerplus resulted in a median 59% decrease in symptoms of bipolar disorder and a 40% decrease in ADHD symptoms.
In the ADHD literature, a 30% decrease in symptom scores is accepted as a good indicator of a clinically significant symptom reduction. In this analysis, 76% of those with ADHD alone showed a 30% reduction in ADHD symptom severity.
On the other hand, the bipolar disorder literature typically uses a 50% reduction as a clinically meaningful change. In this analysis, 46% of participants showed at least a 50% reduction in bipolar symptom severity.
More than half of those on psychiatric medications were able to eliminate them, and those who were still taking medications were able to reduce dosages by 74%. This medication reduction was clearly helpful; 79% of those who reduced psychiatric medications saw symptom improvement.
Researchers concluded that “the results reported here, in combination with the other publications to date, illustrate a consistent pattern of improvements in psychiatric symptoms, providing a powerful case for further research on micronutrient treatment, in particular investment in randomized controlled trials.”
 Click here to read the entire study.
Have you missed an edition of Common Ground Online? Are you new to the Truehope Program? Visit our email archive page for a directory of all previous Common Ground newsletters. These emails are loaded with useful information that can help you succeed on EMPowerplus and the Truehope Program.
Help us to serve you better. Send your questions or comments about the Truehope Program, EMPowerplus, or our support resources to feedback@truehope.com or call 1-888-878-3467 to speak to a Truehope Support Specialist.
We want to provide you with the most accurate and up-to-date program information so that you can continue to make informed decisions regarding your health. Our hope is that you will find hope, healing, and health through education and continued support.
Yours in health,
The Truehope Staff
|
